Allarity Q2 2026: cash $26.9M, loss $3.7M; stenoparib manufacturing completed

Allarity Therapeutics, Inc.

Cash and restricted cash $26.9M at June 30, 2026, up from $14.7M a year ago.
Q2 comprehensive loss $3.7M vs $4.2M; six-month loss $6.5M vs $7.2M.
R&D expenses $1.3M (down from $2.3M); G&A $1.3M (down from $1.8M).
Completed Phase 3-ready stenoparib API manufacturing campaign in July 2026, ahead of schedule.
USPTO granted key patent for stenoparib DRP companion diagnostic, exclusivity to 2042.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.